Pharma Pioneer

First Patient Dosed in Prokarium's PARADIGM-1 NMIBC Trial

29 May 2024
2 min read

Prokarium, a biopharmaceutical firm specializing in synthetic biology, has initiated a Phase I/Ib clinical trial, known as PARADIGM-1, for non-muscle invasive bladder cancer (NMIBC) patients. The first participant has received treatment with ZH9, an experimental immunotherapy being tested for safety and efficacy. The trial is taking place at various US locations and will assess a single intravesical dose of ZH9 under the same Investigational New Drug (IND) application.
Dr. Josefin-Beate Holz, Prokarium's Chief Medical Officer, expressed enthusiasm about the trial's commencement, highlighting its potential to improve NMIBC treatment. Dr. Daniel Zainfeld, a urologist from San Antonio, echoed the sentiment, noting the trial's significance for patients in need of novel therapeutic approaches. Kristen Albright, Prokarium's CEO, thanked the participants and medical professionals involved, emphasizing the company's commitment to developing "Living Cures" through synthetic biology.
Prokarium, headquartered in London, is focused on creating innovative, accessible immunotherapies. Their lead program, the subject of the PARADIGM-1 trial, is a single-dose therapy designed to revolutionize bladder cancer treatment. ZH9, the company's proprietary immunotherapy, is being investigated in the clinical trial to offer a new treatment option for NMIBC patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

REGENXBIO Completes Cohort 2 Enrollment and Reports Positive Interim AFFINITY DUCHENNE® Trial Data
Pharma Pioneer
3 min read
REGENXBIO Completes Cohort 2 Enrollment and Reports Positive Interim AFFINITY DUCHENNE® Trial Data
29 May 2024
REGENXBIO has successfully completed patient recruitment for the second group in the Phase I/II AFFINITY DUCHENNE® clinical trial, which is examining the safety and effectiveness of RGX-202.
Read →
REGENXBIO's RGX-121 MPS II Trial Meets Primary Endpoint
Pharma Pioneer
2 min read
REGENXBIO's RGX-121 MPS II Trial Meets Primary Endpoint
29 May 2024
REGENXBIO Inc. (Nasdaq: RGNX) revealed that the Phase I/II/III CAMPSIITE® clinical trial for RGX-121, a treatment for Mucopolysaccharidosis Type II (MPS II).
Read →
Genenta's Success in Reprogramming GBM Tumor Microenvironment Opens New Paths for Solid Tumor Treatments
Pharma Pioneer
2 min read
Genenta's Success in Reprogramming GBM Tumor Microenvironment Opens New Paths for Solid Tumor Treatments
29 May 2024
Genenta Science, a clinical-stage biotech firm specializing in immuno-oncology, has made significant progress in its Phase 1/2 clinical trial for Temferon™.
Read →
Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
Pharma Pioneer
2 min read
Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
29 May 2024
Belhaven Biopharma announced promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis due to severe allergic reactions.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.